The Clinical Evaluation of Phenylindandione as an Anticoagulant

IN 1944 indandione derivatives were reported by Kabat, Stohlman and Smith1 to be capable of producing hypoprothrombinemia in laboratory animals. These workers studied several compounds with different side chains, but only 2-phenyl-l, 3-indandione was found to have a hypoprothrombinemic effect comparable to that of Dicumarol. In their experience compounds with 3 ketone groups were more effective in producing hypoprothrombinemia than those with 2 ketone groups. In 1947 Meunier, Mentzer and Molho,2 during a study of chemical structures possessing activity against vitamin K, reported phenyl indandione or 2-phenyl-l, 3-indandione to be effective in its hypoprothrombinemic action in laboratory animals; its formula . . .